business
Halozyme Therapeutics (HALO) Proposes $1.05B in Convertibles. Is More Time Worth the Cost?
Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced on September 16 a proposed $1.05 billion offering of convertible senior notes due October 1, 2033. The plan includes an expected option for initial purchasers to buy another $150 million. The interest rate and initial conversion terms were to be determined at pricing. Halozyme Therapeutics, Inc. (NASDAQ:HALO) intends to use [...]
ONLY AVAILABLE IN PAID PLANS
Read Full ArticleShare this story
Up next
Related Stories
UK Prime Minister Burnham says Iran 'played a part' in British air base incident
cnbc.com
Piyush Goyal gets a ‘trade minister for life’ tag from US trade chief at G20
timesofindia.indiatimes.com
Trump touts $200 billion South Korean investment plan as Alaska LNG project hangs in balance
cnbc.com
Cornell rape case: Prosecutor says he wasn't given transcript of Jane Doe's interview with campus police; university agrees to independent investigation, New York governor says
yahoo.com
Passengers and crew foil co-pilot's apparent attempt to crash FlyDubai flight to Israel
cnbc.com